CiToxLAB has increased its inhalation test capabilities in North America and Europe. CiToxLAB-North America has opened a new rodent and non-rodent inhalation facility, adding the ability to evaluate pharmaceuticals, biological compounds and inhalation devices.
 
The studies conducted at the facility will use seven rodent suites and five non-rodent suites, with capabilities to perform studies by the inhalation route in all species. In CiToxLAB-North America, the Canadian team has more than 25 years of cumulative experience in exposure of multiple animal species to single or repeated nose-only and oronasal exposure routes in liquids, powders, vapors and metered dose inhalers.
 
In Europe, CiToxLAB-Hungary is equipped with three rodent suites and one non-rodent suite, doubling its rodent capacity. The new area will be fully operational by the end of 2Q12. The Hungary team of scientists and technicians has a combined 80 years of experience.
 
“We are now able to offer this type of inhalation testing on both sides of the Atlantic and at favorable prices when compared to our competitors,” said Jean-François Le Bigot, chief executive officer of CiToxLAB. “The services offered via the inhalation route in the Hungarian and North American facilities are complementary with the expertise provided by the other facilities, including CiToxLAB-France and CiToxLAB-Scantox in Denmark, which directly highlights the benefits of our acquisition of LAB Research last year.”